Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Goodwill & Intangibles (2017 - 2023)

Historic Goodwill & Intangibles for Aclaris Therapeutics (ACRS) over the last 7 years, with Q4 2023 value amounting to $751000.0.

  • Aclaris Therapeutics' Goodwill & Intangibles fell 8982.38% to $751000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $751000.0, marking a year-over-year decrease of 8982.38%. This contributed to the annual value of $751000.0 for FY2023, which is 8982.38% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Goodwill & Intangibles of $751000.0 as of Q4 2023, which was down 8982.38% from $7.4 million recorded in Q3 2023.
  • Aclaris Therapeutics' Goodwill & Intangibles' 5-year high stood at $92.3 million during Q1 2019, with a 5-year trough of $751000.0 in Q4 2023.
  • Moreover, its 5-year median value for Goodwill & Intangibles was $7.4 million (2019), whereas its average is $15.5 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Goodwill & Intangibles surged by 25727.72% in 2019, and later tumbled by 9200.42% in 2020.
  • Over the past 5 years, Aclaris Therapeutics' Goodwill & Intangibles (Quarter) stood at $25.9 million in 2019, then crashed by 71.49% to $7.4 million in 2020, then changed by 0.0% to $7.4 million in 2021, then changed by 0.0% to $7.4 million in 2022, then plummeted by 89.82% to $751000.0 in 2023.
  • Its last three reported values are $751000.0 in Q4 2023, $7.4 million for Q3 2023, and $7.4 million during Q2 2023.